Alnylam Presents Preclinical Data on AAT Deficiency Drug
November 15, 2012
Alnylam Presents Preclinical Data on AAT Deficiency Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- IP Update: Recent Patents, Patent Applications Awarded to Rosetta, Venganza, Alnylam, and More
June 13, 2013 / Gene Silencing News - As Big Pharma Looks to Niche Diseases, RNAi May Benefit
May 30, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Rosetta, Dicerna, and More
May 30, 2013 / Gene Silencing News - UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 23, 2013 / Gene Silencing News